Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | EPOR | P19235 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8621492 | 0.84 | ACP3 (0.44) | SLC6A4MEN1KMT2ASLC6A9MAPT | |
| SCHEMBL8623419 | 0.83 | SLC6A4 (0.46) | SLC6A4SLC6A9SLC6A2 | |
| SCHEMBL8623278 | 0.80 | FDFT1 (0.42) | SLC6A4 | |
| SCHEMBL8622068 | 0.78 | SLC6A9 (0.48) | SLC6A4MEN1KMT2ASLC6A9 | |
| SCHEMBL8626313 | 0.76 | ACP3 (0.39) | SLC6A4KMT2ASLC6A2 | |
| SCHEMBL8947053 | 0.76 | FDFT1 (0.48) | — | |
| SCHEMBL8620195 | 0.74 | F2 (0.39) | SLC6A4SLC6A9 | |
| SCHEMBL8619830 | 0.74 | SLC6A2 (0.52) | SLC6A4MEN1KMT2ASLC6A9SLC6A2 | |
| SCHEMBL8622280 | 0.74 | SLC6A2 (0.52) | SLC6A4MEN1KMT2ASLC6A9SLC6A2 | |
| SCHEMBL8620194 | 0.72 | SLC6A4 (0.40) | SLC6A4ALDH1A1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | claimed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | claimed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |